<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4330">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818216</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20200914X</org_study_id>
    <secondary_id>3UH3DK114920-04S2</secondary_id>
    <nct_id>NCT04818216</nct_id>
  </id_info>
  <brief_title>Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection</brief_title>
  <acronym>NIRVANA</acronym>
  <official_title>NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized&#xD;
      patients with COVID-19 infection and acute kidney injury to determine the effect of NR on&#xD;
      whole blood nicotinamide adenine dinucleotide (NAD+) levels and to evaluate safety of the use&#xD;
      of NR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study team chose a treatment protocol with NR as a treatment for patients who will be&#xD;
      admitted with COVID-19 related illness and develop AKI after admission. Treatment duration&#xD;
      will be for 10 days and the primary study endpoint will be the change in whole blood NAD+&#xD;
      from baseline to end of treatment in NR group vs placebo group. The study team will evaluate&#xD;
      whole blood NAD+ levels as a marker of efficacy and biological effect of NR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, double-blind, placebo-controlled clinical interventional trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The study drug (NR or placebo) packaging and labeling will be designed to maintain the blinding of the investigator's team and the participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in whole blood NAD+ level</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Measure of NAD+ level in whole blood from treatment beginning to end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events of Grade 3 or Higher</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Safety of NR in hospitalized patients with COVID-19 and AKI (defined as the occurrence of at least one serious adverse event of grade 3 or higher)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Thrombocytopenia</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Number occurrences of thrombocytopenia defined as &gt;25% decline in blood platelet count from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Area under the curve (AUC)</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>To determine the effect of NR on changes in AUC serum creatinine from baseline during the 10-day intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of NR on Major Adverse Kidney Events (MAKE)</measure>
    <time_frame>30 days to 90 days</time_frame>
    <description>Time to first occurrence of MAKE defined as doubling of serum creatinine, the initiation of long-term dialysis, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>30 days to 90 days</time_frame>
    <description>Measurement of change in eGFR at 30-90 days post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Proteinuria</measure>
    <time_frame>30 days to 90 days</time_frame>
    <description>Measurement of change in proteinuria at 30-90 days post randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules will be administered 2 capsules twice daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotinamide Riboside Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotinamide riboside 250mg capsules will be administered 2 capsules twice daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule containing inert ingredient</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Microcrystalline cellulose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinamide riboside</intervention_name>
    <description>250 mg Nicotinamide riboside capsules</description>
    <arm_group_label>Nicotinamide Riboside Group</arm_group_label>
    <other_name>Niagen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form from a participant or legally&#xD;
             authorized representative (LAR);&#xD;
&#xD;
          2. Male or female, &gt;18 years old;&#xD;
&#xD;
          3. Admitted to hospital with a laboratory diagnosis of COVID-19 infection and COVID-19&#xD;
             related illness and evidence of persistent AKI as defined by the Kidney Disease:&#xD;
             Improving Global Outcomes (KDIGO) guidelines during the first 10 days following&#xD;
             admission (Table 3);&#xD;
&#xD;
          4. Willing to adhere to the study intervention regimen;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to nicotinamide riboside (NR);&#xD;
&#xD;
          2. Pregnant or lactating women confirmed with positive laboratory pregnancy tests as per&#xD;
             local requirements;&#xD;
&#xD;
          3. eGFR &lt;15 mL/min/1.73 m2 as per the Chronic Kidney Disease Epidemiology Collaboration&#xD;
             equation at admission lab;&#xD;
&#xD;
          4. Maintenance renal replacement therapy or initiation of renal replacement therapy&#xD;
             before randomization&#xD;
&#xD;
          5. Currently on NR or nicotinamide or vitamin B3 (niacin) supplementation (multivitamins&#xD;
             are allowed);&#xD;
&#xD;
          6. Concomitant cirrhosis of liver or acute liver failure;&#xD;
&#xD;
          7. Any medical history or condition that might, in the opinion of the attending&#xD;
             physician, put the participant at significant risk if he/she were to participate in&#xD;
             the trial;&#xD;
&#xD;
          8. Individuals with kidney transplant;&#xD;
&#xD;
          9. Individuals with blood platelet count &lt;100,000/microL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kumar Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kumar Sharma, MD</last_name>
    <phone>210 567 4700</phone>
    <email>sharmak3@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Subrata Debnath, PhD</last_name>
    <phone>210 567 4700</phone>
    <email>nath@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Subrata Debnath, PhD</last_name>
      <phone>210-567-4700</phone>
      <email>nath@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kumar Sharma, MD</last_name>
      <phone>210 567 4700</phone>
      <email>sharmak3@uthscsa.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Kumar Sharma</investigator_full_name>
    <investigator_title>Holder of the L. David Hillis, M.D. Endowed Chair, Medicine -Renal Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

